Detalhe da pesquisa
1.
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents.
Oncologist
; 29(1): 75-83, 2024 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37548439
2.
Immune-Related Adverse Event Likelihood Score Identifies "Pure" IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population.
Oncologist
; 29(2): e266-e274, 2024 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37715957
3.
HER2-positive breast cancer: cotargeting to overcome treatment resistance.
Curr Opin Oncol
; 35(6): 461-471, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37621172
4.
New Concepts in Cardio-Oncology.
Cancer Treat Res
; 188: 303-341, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38175351
5.
HER2-Low Breast Cancer: a New Subtype?
Curr Treat Options Oncol
; 24(5): 468-478, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36971965
6.
Systemic Treatment of Ductal Carcinoma In Situ of the Breast.
Chirurgia (Bucur)
; 116(5 Suppl): S97-S104, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34967317
7.
Antibody-drug conjugates in breast cancer: the chemotherapy of the future?
Curr Opin Oncol
; 32(5): 494-502, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32657795
8.
Cardiotoxicity of Agents Used in Patients With Breast Cancer.
JCO Oncol Pract
; 20(1): 38-46, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37983586
9.
Circulating tumor cells et al.: towards a comprehensive liquid biopsy approach in breast cancer.
Transl Breast Cancer Res
; 5: 10, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38751670
10.
The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer.
Cancer Treat Rev
; 128: 102761, 2024 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-38772169
11.
Biology and Treatment of HER2-Low Breast Cancer.
Hematol Oncol Clin North Am
; 37(1): 117-132, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36435605
12.
The HER2-low revolution in breast oncology: steps forward and emerging challenges.
Ther Adv Med Oncol
; 15: 17588359231152842, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36844387
13.
Latest advances in clinical studies of circulating tumor cells in early and metastatic breast cancer.
Int Rev Cell Mol Biol
; 381: 1-21, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37739480
14.
Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases.
Eur J Cancer
; 185: 119-130, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36989828
15.
Metaplastic breast cancer: an all-round multidisciplinary consensus.
Eur J Cancer Prev
; 32(4): 348-363, 2023 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37021548
16.
Antibody-Drug Conjugates in Breast Cancer: What Is Beyond HER2?
Cancer J
; 28(6): 436-445, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36383906
17.
PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative.
J Pers Med
; 12(11)2022 Oct 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-36579519
18.
Combination immunotherapy strategies for triple-negative breast cancer: current progress and barriers within the pharmacological landscape.
Expert Rev Clin Pharmacol
; 15(12): 1399-1413, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36317756
19.
Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe?
Eur J Cancer
; 171: 25-42, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35696887
20.
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives.
Cancer Treat Rev
; 106: 102395, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35468539